{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:05Z","timestamp":1788716465718,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10067-018-4073-7","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T07:00:42Z","timestamp":1522047642000},"page":"2027-2034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-6216","authenticated-orcid":false,"given":"Masei","family":"Suda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokutaro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"4073_CR1","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/acr.22365","volume":"66","author":"A Makol","year":"2014","unstructured":"Makol A, Davis JM 3rd, Crowson CS, Therneau TM, Gabriel SE, Matteson EL (2014) Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007. Arthritis Care Res (Hoboken) 66:1482\u20131488","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4073_CR2","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381\u20133390","journal-title":"Arthritis Rheum"},{"key":"4073_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, Gough AK, Green MJ, Helliwell PS, Keenan AM, Morgan AW, Quinn M, Reece R, van der Heijde DM, Wakefield RJ, Emery P (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73:75\u201385","journal-title":"Ann Rheum Dis"},{"key":"4073_CR4","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1136\/ard.2004.030908","volume":"64","author":"EH Choy","year":"2005","unstructured":"Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL, Intramuscular Methylprednisolone Study Group (2005) A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 64:1288\u20131293","journal-title":"Ann Rheum Dis"},{"issue":"suppl 4","key":"4073_CR5","first-page":"iv9","volume":"51","author":"JW Bijlsma","year":"2012","unstructured":"Bijlsma JW (2012) Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 51(suppl 4):iv9\u2013iv13","journal-title":"Rheumatology"},{"key":"4073_CR6","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar2591","volume":"11","author":"T Sokka","year":"2009","unstructured":"Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, Skakic V, Badsha H, Peets T, Baranauskaite A, G\u00e9her P, Ujfalussy I, Skopouli FN, Mavrommati M, Alten R, Pohl C, Sibilia J, Stancati A, Salaffi F, Romanowski W, Zarowny-Wierzbinska D, Henrohn D, Bresnihan B, Minnock P, Knudsen LS, Jacobs JW, Calvo-Alen J, Lazovskis J, Pinheiro Gda R, Karateev D, Andersone D, Rexhepi S, Yazici Y, Pincus T, QUEST-RA Group (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 11:R7","journal-title":"Arthritis Res Ther"},{"key":"4073_CR7","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"4073_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1136\/ard.2009.124958","volume":"69","author":"MC Goes van der","year":"2010","unstructured":"van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JW (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69:1913\u20131319","journal-title":"Ann Rheum Dis"},{"key":"4073_CR9","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK (2017) Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357:j1415","journal-title":"BMJ"},{"key":"4073_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/ard.2009.114579","volume":"69","author":"MC Goes van der","year":"2010","unstructured":"van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Guillevin L, Holland M, Kirwan JR, Rovensky J, Saag KG, Severijns G, Webber S, Westhovens R, Bijlsma JW (2010) Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 69:1015\u20131021","journal-title":"Ann Rheum Dis"},{"key":"4073_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","volume":"136","author":"AA Everdingen van","year":"2002","unstructured":"van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1\u201312","journal-title":"Ann Intern Med"},{"key":"4073_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1136\/ard.2003.014050","volume":"63","author":"HA Capell","year":"2004","unstructured":"Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, Thomson EA, Hampson R, Poon FW (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63:797\u2013803","journal-title":"Ann Rheum Dis"},{"key":"4073_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2005.038638","volume":"65","author":"JA Silva Da","year":"2006","unstructured":"Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, In\u00eas LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65:285\u2013293","journal-title":"Ann Rheum Dis"},{"key":"4073_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","volume":"96","author":"KG Saag","year":"1994","unstructured":"Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, Kohler JA, Furst DE (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115\u2013123","journal-title":"Am J Med"},{"key":"4073_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit F (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis 75:952\u2013957","journal-title":"Ann Rheum Dis"},{"key":"4073_CR16","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1056\/NEJM196906262802601","volume":"280","author":"RR MacGregor","year":"1969","unstructured":"MacGregor RR, Sheagren JN, Lipsett MB, Wolff SM (1969) Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med 280:1427\u20131431","journal-title":"N Engl J Med"},{"key":"4073_CR17","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJM197411282912203","volume":"291","author":"DC Dale","year":"1974","unstructured":"Dale DC, Fauci AS, Wolff SM (1974) Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 291:1154\u20131158","journal-title":"N Engl J Med"},{"key":"4073_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","volume":"82","author":"GG Hunder","year":"1975","unstructured":"Hunder GG, Sheps SG, Allen GL, Joyce JW (1975) Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82:613\u2013618","journal-title":"Ann Intern Med"},{"key":"4073_CR19","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","volume":"11","author":"AE Stuck","year":"1989","unstructured":"Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954\u2013963","journal-title":"Rev Infect Dis"},{"key":"4073_CR20","doi-asserted-by":"crossref","unstructured":"Migita K, Sasaki Y, Ishizuka N, Arai T, Kiyokawa T, Suematsu E, Yoshimura M, Kawabe Y, Matsumura R, Akagawa S, Mori S, Shirai M, Watanabe Y, Minami N, Soga T, Owan I, Ohshima S, Yoshizawa S, Matsui T, Tohma S, Bito S (2013) Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. Medicine 92(5):285","DOI":"10.1097\/MD.0b013e3182a72299"},{"key":"4073_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/cid\/ciw345","volume":"63","author":"A Mor","year":"2016","unstructured":"Mor A, Berencsi K, Nielsen JS, Rungby J, Friborg S, Brandslund I, Christiansen JS, Vaag A, Beck-Nielsen H, S\u00f8rensen HT, Thomsen RW (2016) Rates of community-based antibiotic prescriptions and hospital-treated infections in individuals with and without type 2 diabetes: a Danish nationwide cohort study, 2004-2012. Clin Infect Dis 63:501\u2013511","journal-title":"Clin Infect Dis"},{"key":"4073_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P6 Wells GA (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386:258\u2013265","journal-title":"Lancet"},{"key":"4073_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","volume":"47","author":"VF Panoulas","year":"2008","unstructured":"Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72\u201375","journal-title":"Rheumatology (Oxford)"},{"key":"4073_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764\u2013770","journal-title":"Ann Intern Med"},{"key":"4073_CR25","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.108.790048","volume":"118","author":"H Ueshima","year":"2008","unstructured":"Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, Nakamura Y, Okamura T (2008) Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118:2702\u20132709","journal-title":"Circulation"},{"key":"4073_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/art.1780240705","volume":"24","author":"OS Gluck","year":"1981","unstructured":"Gluck OS, Murphy WA, Hahn TJ, Hahn B (1981) Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum 24:892\u2013898","journal-title":"Arthritis Rheum"},{"key":"4073_CR27","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.3899\/jrheum.081188","volume":"36","author":"CS Crowson","year":"2009","unstructured":"Crowson CS, Rahman MU, Matteson EL (2009) Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol 36:1606\u20131610","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4073-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4073-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4073-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:30Z","timestamp":1751500830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4073-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4073-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of St. Luke\u2019s International Hospital (approval number, 14-R162).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}